UC Irvine - Faculty Profile System

Dr. Steven N. Seyedin

Claim this profile

UC Irvine Health/Chao Family Comprehensive Cancer Center

Studies Prostate Adenocarcinoma
Studies Prostate Cancer
5 reported clinical trials
16 drugs studied

Affiliated Hospitals

Image of trial facility.
UC Irvine Health/Chao Family Comprehensive Cancer Center
Image of trial facility.
UCSF Medical Center-Mission Bay

Clinical Trials Steven N. Seyedin is currently running

Image of trial facility.

Relugolix + Radiation

for Advanced-Stage Prostate Cancer

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.
Recruiting0 awards Phase 2
Image of trial facility.

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3

More about Steven N. Seyedin

Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Steven N. Seyedin has experience with
  • Apalutamide
  • Bicalutamide
  • Buserelin
  • Degarelix
  • Flutamide
  • Goserelin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Steven N. Seyedin specialize in?
Is Steven N. Seyedin currently recruiting for clinical trials?
Are there any treatments that Steven N. Seyedin has studied deeply?
What is the best way to schedule an appointment with Steven N. Seyedin?
What is the office address of Steven N. Seyedin?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security